ORIGINAL RESEARCH ARTICLE

# miRNA–mRNA Interaction Network in Non-small Cell Lung **Cancer**

Ruiqi Ma<sup>1</sup> • Chenyu Wang<sup>2</sup> • Junjian Wang<sup>3</sup> • Dong Wang<sup>4</sup> • Jianzhen Xu<sup>1</sup>

Received: 14 November 2014 / Revised: 3 January 2015 / Accepted: 9 February 2015 / Published online: 4 September 2015 - International Association of Scientists in the Interdisciplinary Areas and Springer-Verlag Berlin Heidelberg 2015

Abstract MicroRNAs (miRNAs) are small RNA molecules, about 20–25 nucleotides in length. They repress or degrade messenger RNA (mRNA) translation, which are involved in human cancer. In this study based on paired miRNA and mRNA expression profiles of non-small cell lung cancer samples, we constructed and analyzed miRNA–mRNA interaction network via several bioinformatics softwares and platforms. This integrative network is comprised of 249 nodes for mRNA, 90 nodes for miRNA and 290 edges that show regulations between target genes and miRNAs. The three miR-1207-5p, miR-1228\* and miR-939 are the most connected miRNA that regulated a large number of genes. ST8SIA2, MED1 and HDAC4, SPN, which are targeted by multiple miRNAs and located in the center of the network, are involved in both lung cancer and nervous system via functional annotation

Electronic supplementary material The online version of this article (doi: $10.1007$ /s12539-015-0117-8) contains supplementary material, which is available to authorized users.

& Dong Wang wangdong@ems.hrbmu.edu.cn

 $\boxtimes$  Jianzhen Xu xujz0451@gmail.com

- <sup>1</sup> College of Bioengineering, Henan University of Technology, Zhengzhou 450001, China
- <sup>2</sup> Department of General Surgery, Huaihe Clinical College of Henan University, Kaifeng 475000, China
- Cancer center, University of California at Davis, Sacramento, CA 95817, USA
- <sup>4</sup> College of Bioinformatics Science and Technology, Harbin Medical University, Harbin 150081, China

analysis. Such a global interaction network of miRNA– mRNA in lung cancer will contribute to refining miRNA target predictions and developing novel therapeutic candidates.

Keywords Lung cancer · miRNA-mRNA interactions · **Bioinformatics** 

# 1 Introduction

Lung cancer has become the most common cancer among men and women (13.0 % of the total) in the world. In 2012, among men, lung cancer was the highest incidence cancer (16.7 % of the total), and it was also the most common causes of cancer death (23.6 %). The estimated age-standardized rates (ASRs) in the incidence and mortality were 34.2 per 100,000 and 30.0 per 100,000, and both were the highest in cancer [[1\]](#page-9-0). Among women, it was the third most common cancer (8.7 % of the total). Lung cancer was also the second most common cause of cancer death (13.8 %). Because of the poor survival of lung cancer, the 5-year prevalence (1.9 million) is very close to the annual mortality (1.6 million) [\[1](#page-9-0)]. Squamous cell lung carcinoma (SCC), lung adenocarcinoma (AD) and large cell lung carcinoma (LCLC) are three main types of non-small cell lung cancers (NSCLCs), which account 83.2 % of lung cancers [[2\]](#page-9-0).

miRNAs are small noncoding RNAs (20–25 nucleotides in length) that make gene expression silence posttranscriptionally through binding to their target mRNAs by the 3' untranslated regions (3'UTRs). Mature miRNAs and argonaute protein are incorporated into an RNA-induced silencing complex (RISC) [[3,](#page-9-0) [4\]](#page-9-0). RISC guides to its mRNA target in the cytoplasm by the associated miRNA. There



are two primary systems used to control mRNA expression: inhibition of mRNA translation and mRNA degradation. The higher the degree of base pairing between the miRNA and the mRNA, the more likely the target mRNA will be degraded [[5\]](#page-9-0). In some conditions, miRNAs can positively regulate gene expression; however, the underlying mechanisms are not clearly elucidated [\[4](#page-9-0)].

miRNAs can modulate many biological processes including development, differentiation, proliferation, cell death, and playing an important role in the pathogenesis of different tumor types [\[3](#page-9-0), [6–9\]](#page-9-0). In lung cancers, Yanaihara et al. [\[10](#page-9-0)] reported that the low overall survival in AD was related to high miR-155 and low let7a-2 expression. Hu et al. [[11\]](#page-9-0) reported that a four-miRNA signature (miR-486, miR-30d, miR-1 and miR-499) could predict overall survival for NSCLC independently. Yu et al. [\[12](#page-9-0)] found that a five-miRNA signature (miR-137, miR-372, miR-182\*, miR-221 and let-7a) was related to disease-free survival in NSCLC. Lebanony et al. [\[13](#page-9-0)] discovered that miR-205 was a highly specific biomarker for SCC.

However, there is no global analysis of the miRNA– mRNA interaction network in lung cancers. Such a systems level approach can bring a new way to understand the complex biological processes. In this study, based on pairmatched miRNA–mRNA expression profile of NSCLC samples, we constructed and analyzed the miRNA–mRNA interaction network through a number of bioinformatics tools and platforms.

## 2 Materials and Methods

#### 2.1 miRNA and mRNA Expression Profiles

In the past dozen years, the growth in number of miRNA and mRNA expression profiles is exponential. Large numbers of expression profiles are available freely from databases Gene Expression Omnibus (GEO; [www.ncbi.](http://www.ncbi.nlm.nih.gov/geo) [nlm.nih.gov/geo\)](http://www.ncbi.nlm.nih.gov/geo) [[14\]](#page-9-0). We download the miRNA and mRNA expression profiles from GEO (Accession Number GSE29250 [\[15](#page-9-0)]). This expression profile includes 12 pairmatched samples including 6 NSCLC tissues and their matching normal control from adjacent tissues. Genomewide analysis of miRNA expression and gene expression in NSCLC were parallel measured at Illumina Human v2 MicroRNA expression beadchip and HumanHT-12 V4.0 expression beadchip platforms. When multiple probes for a particular gene, we calculated its signal intensity as the mean of intensities of all these probe sets in this sample. The raw signal was normalized by robust multi-array average (RMA) normalization procedure to produce expression values [\[16](#page-9-0)].

## 2.2 miRNA–mRNA Interactions Analysis and Visualization

We integrated above miRNA–mRNA expression profiles data by MAGIA tool [\(http://gencomp.bio.unipd.it/magia\)](http://gencomp.bio.unipd.it/magia) [\[17](#page-9-0)]. MAGIA first predicts the miRNA target by PITA, miRanda, TargetScan or Boolean combinations of these algorithms. Then, MAGIA combined miRNA targets with different statistical measures, such as Spearman and Pearson correlation and mutual information, to construct miRNA–mRNA bipartite networks. The complete list of identified significant interactions can be imported into other softwares, to allow further visualization and processing. To account for the multiple hypothesis testing, the q value is used to select significant results. Q value is a variant of the traditional  $p$  value but correcting for multiple comparisons.

In this study, we chose EntrezGene IDs, Pearson correlation measure and the intersection of PITA (score filter: -10) and miRanda (score filter: 500) target prediction algorithms. Since the data are normally distributed data and medium–large sample size  $(>5)$ , Pearson correlation measure is used for miRNA–mRNA expression correlation. The miRNAs–mRNAs interaction network was visualized by Cytoscape [\[18](#page-9-0), [19\]](#page-9-0). This software can get a visualization of nodes and edges as a two-dimensional network and change network factor, such as shape, color and size, based on attribute values. It also supports a number of automated network layout algorithms.

# 2.3 Functional Analysis Via GO, Pathways and Human Disease Resources

To elucidate the functional significances of identified miRNA–mRNA interactions, we combined GeneDecks, DAVID and Malacard to analyze gene ontology, pathway information and human disease information by list of significant down-regulated target genes in lung cancer miRNA–mRNA interactions network.

DAVID [[20\]](#page-9-0) (The Database for Annotation, Visualization and Integrated Discovery) Bioinformatics Resources [\(http://david.abcc.ncifcrf.gov/](http://david.abcc.ncifcrf.gov/)) is a tool to gain biological features/meaning through large gene lists. It is useful to understand biological themes. GeneDecks [[21\]](#page-9-0) [\(http://](http://www.genecards.org/genedecks) [www.genecards.org/genedecks\)](http://www.genecards.org/genedecks) can analyze the gene through sharing the same descriptors, using the built-in rich annotation of human gene in the GeneCards (a searchable, integrated tool of annotation information about human genes [\[22](#page-9-0)]). GeneDecks can provide the information about disorders, drug relationships, pathways, etc, by gene lists. Malacard (<http://www.malacards.org/>) [[23\]](#page-9-0) is an integrated database of human disorder and their annotations. This database lists the genes related to lung cancer. We can compare these lung cancer-related genes with the downregulated target genes, which are provided by MAGIA. We always used the default settings in the GeneDecks, DAVID and Malacard analysis.

## 3 Results

# 3.1 Construction of miRNA–mRNA Interaction Network

Each patient has four profiling arrays measured the miRNA and mRNA expression together with their adjacent normal tissues. The characteristics of samples are given in Table S1. After normalization, the expression matrix was input into MAGIA pipeline, and an aggregate number of 290, 6230, 31,249 miRNA–mRNA interactions with correlations  $\langle -0.75, \langle -0.50, \langle -0.25, \rangle \rangle$  respectively, were identified. Figure [1,](#page-3-0) Fig. S1 and Fig. S2 show the global miRNA–mRNA interaction network in lung cancer, respectively based on the correlations  $\langle -0.75, \, \langle -0.50, \, \rangle$  $<-0.25$ . We chose the genes whose correlations  $<-0.75$ as highly negative correlated genes for follow-up analysis.

This network consists of 249 nodes for mRNA, 90 nodes for miRNAs and 290 edges that show regulations between these miRNAs and mRNAs. In total, the network involved 61 connected components, including 36 single edges, 11 double edges and 14 triple edges or with more than three edges. These types of connected components, respectively, involve 72, 33 and 234 nodes. Statistics of the connected components is shown in Fig. [2](#page-4-0). These results indicated that the majority of miRNAs and their targets can be integrated into a big interlocking network.

In this network, miRNAs (presented in triangle and colored in pink as shown in Fig. [1\)](#page-3-0) usually located in the center of the interaction network or module, while mRNAs (circular and sky blue nodes as shown in Fig. [1](#page-3-0)) are in the external of the interaction network or module.

According to Fig. [1,](#page-3-0) we found three miRNAs (miR-1207-5p, miR-1228\* and miR-939) regulating 105 target mRNA, occupying 42.17 % of the total mRNA (249 target mRNA). In addition, 30 mRNAs are regulated by more than one miRNA. These mRNAs and their interactional miRNA are indicated in Table [1.](#page-5-0) From expression profile, hsa-miR-1228\* and hsa-miR-939 were down-regulated in NSCLC (Table S2), suggesting their protective roles in normal tissues.

#### 3.2 mRNA Analysis in Lung Cancer

MalaCards is an integrated database of human disorders and their annotations, which can quantitatively measure degree of relationship of interested genes to certain disorders. Using MalaCards, we found that total 35 genes had a confirmed role in lung cancer, occupying 14.06 % in the total 249 mRNAs. The results are given in Table [2.](#page-7-0)

HDAC4, MED1, SPN and ST8SIA2 appear in both Tables [1](#page-5-0) and [2.](#page-7-0) These four genes are regulated by more than one miRNA in lung cancer (Table [1](#page-5-0)) and their relationships to lung cancer were confirmed in previous reports (Table [2](#page-7-0)). Compared with the adjacent normal tissue, these mRNAs increase up to 2.5-fold changes, indicating that they potentially play an important role in miRNA–mRNA interaction network in lung cancer (Table S2).

#### 3.3 Functional Annotation Analysis

Using DAVID and GeneDecks, we studied the functional annotations for mRNAs in the miRNA–mRNA interaction network. The results are given in Table [3.](#page-8-0)

Using DAVID, the result shows that the significant category of Gene Ontology (GO)-molecular function includes seven terms. The most important molecular function is transferase activity (35 genes). The other identified categories, which ranked 2–6, are subsets of transferase activity (Table [3](#page-8-0)). The most important biological processes are cellular process (143 genes), localization (49 genes) and regulation of gene expression (47 genes). The core of cellular components of genes is intracellular part (147 genes), plasma membrane part (38 genes) and organelle membrane (23 genes). The complete GO categories and included genes are given in Table S3.

Utilizing GeneDecks to analyze these 249 target miRNA, the miRNAs are classified into seven types of descriptors in phenotype attribution. The most three important descriptors are mortality/aging (67 genes), nervous system phenotype (63 genes) and growth/size /body phenotype (54 genes). Only one pathway—axon guidance—was found in significantly in our analysis (six genes). The complete analytical results are given in Table S4.

## 4 Discussion

# 4.1 Significant miRNA and mRNA in the Interaction Network

Many miRNAs are abnormally expressed in lung cancer and play a core role in the process of malignant transformation, angiogenesis and tumor metastasis [[10–13,](#page-9-0) [24](#page-9-0)]. Individual miRNA may regulate and control multiple target mRNA involved in different oncogenic or tumor suppressor pathways. Analyzing the miRNA–mRNA interaction network at systems level may open a new chapter in lung <span id="page-3-0"></span>Fig. 1 Interaction network of miRNAs–mRNAs in lung cancer by cytoscape 3 software. MiRNAs are presented in triangle and colored in pink, while mRNAs are expressed by circular and in sky blue



cancer, which will be helpful in elucidating disease mechanisms, providing better targeted agents and finding sensitive early biomarkers [\[6](#page-9-0)].

In this study, we constructed and analyzed the interaction network of miRNA and their target miRNA in lung cancer by using bioinformatics tools and matched mRNA, miRNA expression profiles data. This study showed that 105 of 249 mRNA in the network are down-regulated by three miRNA, miR-1207-5p, miR-1228\* and miR-939. miR-1207-5p regulated the most number of mRNA in the interaction network. Chen et al. [[25\]](#page-9-0) reported that the expression of miR-1207-5p was significantly decreased in gastric cancer tissues compared with the adjacent tissues. miR-1207-5p could bind to the human telomerase reverse transcriptase (hTERT)  $3'$  UTR and down-regulate expression of hTERT. hTERT can reverse telomere shortening, as the catalytic subunit of telomerase, and then prevent proliferation, reduce invasion and induced cell cycle arrest in

<span id="page-4-0"></span>

Fig. 2 The statistics of connected components. There are 36 single edges, 11 double edges and 14 triple edges or with more than three edge components. These types of connected components, respectively, involve 72, 33 and 234 nodes

gastric cancer cells in vitro. Loss of miR-1207-5p may boost hTERT protein expression and elevate the development of gastric cancer. Previous reports indicated that hTERT gene amplification causes hTERT overexpression in lung adenocarcinoma and is an independent poor prognostic marker in NSCLC [[26\]](#page-9-0). But there is no clear evidence on the relationship between miR-1207-5p and hTERT in NSCLC. Our analysis firstly pointed out miR-1207-5p as an important regulator in miRNA–mRNA interaction network.

miR-1228\* was significantly decreased in human gastric cancer tissues compared with normal tissues. Overexpression of miR-1228\* prevented xenograft tumor formation in vivo using the tumor xenograft model. Selective restoration of miR1228\* might be advantageous for therapy of gastric cancer [\[27](#page-9-0)]. miR-939 is substantially highly expressed in ADC compared with their age- and gendermatched control sera [[28\]](#page-10-0). miR-939 may have relevance for early diagnostic biomarker of ADC. But its mRNA targets and molecular mechanism are unknown. Both miR-1228\* and miR-939 are found as essential nodes in our network analysis. Furthermore, our analysis provided the refined mRNA targets and potential mechanistic understanding of the two miRNAs.

#### 4.2 Significant mRNAs in the Interaction Network

HDAC4, MED1, SPN and ST8SIA2 were identified as the most important controlled genes in this interaction network because they are regulated by more than one miRNA in lung cancer (Table [1\)](#page-5-0) and their contribution to lung cancer were confirmed in previous reports (Table [2](#page-7-0)).

SPN (sialophorin) is known as CD43. In the interaction network, it linked to four miRNAs (miR-939, miR-1224-3p,

miR-1236 and miR-1207-5p). Normally, SPN is produced by white blood cells as a transmembrane sialoglycoprotein. Its main cellular functions are intercellular adhesion, intracellular signaling, apoptosis, migration and proliferation [\[29](#page-10-0)]. But abnormal expression has been found in cancers, including adenoid cystic carcinoma [[30,](#page-10-0) [31](#page-10-0)], SCLC and NSCLC. Fu et al. [[29\]](#page-10-0) found that SPN could cause lung cancer pathogenesis by various ways, including preventing malignant cells from NK attack and apoptosis, driving metastasis by mechanisms of anti-adhesion, pro-adhesion and migration. MED1 (mediator complex subunit 1) is regulated by three miRNA (miR-1207-5p, miR-1224-3p and miR-30c-2\*). Kim et al. [[32\]](#page-10-0) demonstrated that the loss of MED1 expression was highly correlated with increased rates of invasion and metastasis in NSCLC. Knockdown of MED1 in NSCLC cell lines results in the change of mRNA levels of the metastasis-related genes. These results indicate that MED1 regulate the invasion and metastasis of NSCLC by regulating the expression of multifold metastasis-related genes. HDAC4 (histone deacetylase 4) gene is linked to two miRNA (miR-1270 and miR-1207-5p). HDAC4 encodes a histone deacetylase and represses gene transcription by influencing transcription factor access to DNA in cells [\[33](#page-10-0)]. Previously, HDAC4 is reported to influence cell differentiation in other types of cancer, such as leukemia [[34,](#page-10-0) [35](#page-10-0)]. But its role in lung development of HDAC4 is unclear. ST8SIA2 (ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 2) is regulated by two miRNA (miR-623 and miR-1182). ST8SIA2 can synthesize polysialic acid (PSA) independently and transfer sialic acid through alpha-2, 8-linkages to the alpha-2, 3-linked and alpha-2, 6-linked sialic acid of N-linked oligosaccharides of glycoproteins [\[36](#page-10-0)]. Tanaka et al. [[37,](#page-10-0) [38](#page-10-0)] indicated that PSA played an important role in tumor development, particularly formation of metastatic foci, and was associated with a poor postoperative prognosis and specifically expressed in advanced-stage NSCLC.

Our analysis of miRNA–mRNA provided many potential miRNA regulators of these four genes, uncovering another layer of modulation on lung cancer initiation and development at global level. It should be noted that all of these genes are targeted by more than one miRNA modulator, indicating that the combined effects of multiple miRNAs may play an important role in lung cancers.

#### 4.3 Significant Gene Ontology Annotations

The result of gene ontology annotation manifested the molecular function is concentrated in transferase activity. Five terms of molecular function are subsets of transferase activity. The smallest subset is protein serine/threonine kinase activity, and it is a subset of all other terms about

No	Gene name	Explanation	<b>MiRNA</b>	Correlation	q value
1	C17orf107	Hypothetical protein LOC100130311	miR-1207-5p	$-0.857$	0.295
			$miR-659$	$-0.782$	0.552
2	CAMK2N2	Calcium-/calmodulin-dependent protein kinase II inhibitor 2	$m$ iR-659	$-0.860$	0.278
			miR-1207-5p	$-0.797$	0.515
3	CREB3L3	cAMP responsive element binding protein 3-like 3	miR-1231	$-0.824$	0.416
			miR-939	$-0.772$	0.578
4	<b>GFAP</b>	Glial fibrillary acidic protein	miR-1268	$-0.799$	0.507
			$miR-593*$	$-0.773$	0.576
5	GPR114	G protein-coupled receptor 114	$miR-541$	$-0.770$	0.587
			miR-149*	$-0.766$	0.598
6	HDAC4	Histone deacetylase 4	miR-1270	$-0.920$	0.057
			miR-1207-5p	$-0.780$	0.558
7	LOC100130494	Hypothetical LOC100130494	$m$ iR-650	$-0.814$	0.446
			miR-1228*	$-0.785$	0.548
8	MUC17	Mucin 17, cell surface associated	miR-939	$-0.806$	0.479
			miR-1207-5p	$-0.780$	0.555
9	<b>P704P</b>	Prostate-specific P704P	miR-518c*	$-0.754$	0.626
			miR-1207-5p	$-0.751$	0.628
10	PCSK7	Proprotein convertase subtilisin/kexin type 7 (pseudogene)	miR-339-5p	$-0.800$	0.505
			$miR-608$	$-0.751$	0.628
11	PLA <sub>2</sub> G <sub>2</sub> D	Phospholipase A2, group IID	$m$ iR-921	$-0.874$	0.203
			miR-1303	$-0.752$	0.628
12	PPM1H	Protein phosphatase 1H (PP2C domain containing)	$m$ iR-663b	$-0.872$	0.208
			$miR-637$	$-0.751$	0.628
13	PRH <sub>2</sub>	Proline-rich protein HaeIII subfamily 1; proline-rich protein	$m$ i $R-491-5p$	$-0.823$	0.417
		HaeIII subfamily 2	miR-939	$-0.765$	0.598
14	RAB3A	RAB3A, member RAS oncogene family	$m$ iR-185*	$-0.862$	0.270
			$miR-1226*$	$-0.775$	0.571
15	RP121O18.1	Kazrin	miR-1207-5p	$-0.824$	0.416
			miR-1224-3p	$-0.777$	0.566
16	SECTM1	Secreted and transmembrane 1	$miR-298$	$-0.787$	0.546
			$m$ iR-92 $b*$	$-0.760$	0.613
17	SLC6A17	Solute carrier family 6, member 17	$m$ iR-130 $b*$	$-0.835$	0.378
			$miR-877$	$-0.778$	0.564
18	ST8SIA2	ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 2	$miR-623$	$-0.853$	0.311
			miR-1182	$-0.751$	0.629
19	SYN1	Synapsin I	miR-939	$-0.815$	0.442
			miR-193b*	$-0.756$	0.622
20	SYNPO <sub>2</sub>	Synaptopodin 2	miR-920	$-0.789$	0.541
			$m$ iR-1226*	$-0.785$	0.548
21	ZBTB24	Zinc finger and BTB domain containing 24	$miR-623$	$-0.777$	0.566
			miR-1202	$-0.765$	0.598
22	ZBTB44	Zinc finger and BTB domain containing 44	miR-1207-5p	$-0.896$	0.131
			miR-518c*	$-0.850$	0.329
23	<b>ZNF498</b>	Zinc finger protein 498	$miR-125a-3p$	$-0.827$	0.407
			miR-1226*	$-0.784$	0.548

<span id="page-5-0"></span>Table 1 The genes in the miRNA–mRNA network, which are regulated by more than one miRNA

Table 1 continued



transferase activity in this analysis. Some members of serine/threonine kinases, such as protein kinase C (PKC), are involved in NSCLC [\[39](#page-10-0)]. They play a key role in cancer cell proliferation, polarity and survival [[40\]](#page-10-0).

There are seven GO terms involved in biological processes regulation. The term of regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process and the term of regulation of nitrogen compound metabolic process shared the completely same genes. The term of regulation of transcription is a subset of above two terms. The genes of regulation of cellular carbohydrate catabolic process and regulation of carbohydrate catabolic process are the same. The other regulation involves gene expression and macromolecule biosynthetic process. Most genes of the above terms are attached to the term of cellular process. Overall, these results suggested that lung cancer is derived from systemic dysfunction of various cellular aspects.

Lung cancer is a type of respiratory system disorder. Interestingly, we found that 63 network refined genes were classified as the nervous system phenotype and 25 genes were classified as the nervous system development (Table [3](#page-8-0)). Combining above two lists, we get 67 non-redundant genes associated with the nervous system. Among them, 21 genes have been associated with lung cancer in other reports (given in Table [2](#page-7-0) by adding an asterisk (\*) in Gene name column). It is worth mentioning that the genes ST8SIA2, MED1 and HDAC4, which are regulated by more than one miRNA in this miRNA–mRNA interaction network, appeared again here. Thus, the three genes may influence both lung cancer and nervous system.

The relationship between nervous system and lung cancers has been noticed in other's studies. For example, [\[41](#page-10-0)] and Stephanie [\[42](#page-10-0)] found that NSCLC often affects the central nervous system (CNS). CNS frequently causes the decline of the life quality and the shortened survival as a complication. But at the same time, the available treatment options are limited. So focusing on the genes that both are related to NSCLC and nervous system may provide a novel approach to treat these complications.

<span id="page-7-0"></span>Table 2 The genes in the miRNA–mRNA network, which are related to lung cancer (provided by Malacards)



These genes by adding asterisk (\*) in Gene name column represent that are related to nervous system. The details will be discussed in Sects.  $4.2$  and  $4.3$ . The correlation score and q value were given by MAGIA

<span id="page-8-0"></span>Table 3 GO categories for the target genes that are participate in miRNAs–mRNAs interactions in cancer

Category/attribution	Term/descriptors		Count $p$ value
GO-molecular function (by DAVID)	Transferase activity	35	0.012
	Transferase activity, transferring phosphorus-containing groups	23	0.008
	Kinase activity	22	0.003
	Phosphotransferase activity, alcohol group as acceptor	19	0.007
	Protein kinase activity	16	0.014
	Protein serine/threonine kinase activity	12	0.026
	Transcription cofactor activity	10	0.049
GO-cellular component (by	Intracellular part	147	0.043
DAVID)	Plasma membrane part	38	0.041
	Organelle membrane	23	0.021
	Golgi apparatus	19	0.028
	Endomembrane system	18	0.021
	Vesicle	15	0.045
	Synapse	10	0.037
	Anchored to membrane	8	0.022
	Synapse part	8	0.037
	Vesicle membrane	6	0.043
	Clathrin-coated vesicle membrane	4	0.029
	Synaptic vesicle membrane	3	0.034
GO-biological process (by DAVID)	Cellular process	143	0.049
	Localization	49	0.035
	Regulation of gene expression	47	0.037
	Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process	46	0.043
	Regulation of macromolecule biosynthetic process	46	0.047
	Regulation of nitrogen compound metabolic process	46	0.049
	Regulation of transcription	43	0.045
	Nervous system development	25	0.005
	Phosphorylation	17	0.044
	Protein amino acid phosphorylation	16	0.021
	Small GTPase-mediated signal transduction	10	0.015
	Skeletal system development	10	0.019
	Enzyme-linked receptor protein signaling pathway	10	0.029
	Secretion by cell	7	0.047
	Neurotransmitter transport	5	0.0207
	Establishment or maintenance of cell polarity	4	0.0237
	Mammary gland development	4 3	0.045 0.017
	Regulation of cellular carbohydrate catabolic process Regulation of carbohydrate catabolic process	3	0.017
Phenotype (by GeneDecks)	Mortality/aging	67	$2.18E - 11$
	Nervous system phenotype	63	$7.77E - 16$
	Growth/size/body phenotype	54	$1.20E - 09$
	Behavior/neurological phenotype	50	$4.90E - 11$
	Homeostasis/metabolism phenotype	50	$1.01E - 06$
	Cellular phenotype	48	$1.13E - 08$
	Craniofacial phenotype	23	$9.45E - 07$
Kegg pathway (by DAVID)	Axon guidance	6	0.012

## <span id="page-9-0"></span>5 Conclusion

The expression profiles of miRNAs and mRNAs in matched samples provided a good opportunity to construct miRNA–mRNA interaction network via bioinformatics tools. In this system-level analysis, we found a number of master miRNAs and mRNAs, which are potentially important for lung cancer initiation and development. This global interaction network of miRNA–mRNA will contribute to refine miRNA target predictions and developing novel therapeutic candidates.

Acknowledgments This work was supported by the National High Technology Research and Development Program of China (863 Program, Grant No. 2014AA021102), the National Natural Science Foundation of China (U1304311, 31100901), China Postdoctoral Science Foundation funded Project (2013M531064, 2014T70363), Natural Science Foundation of Heilongjiang Province of China (QC2010012), Heilongjiang Postdoctoral Foundation (LBH-Z12171).

## References

- 1. Stewart BW, Wild CP (eds) (2014) World cancer report 2014. World Health Organization Press, Geneva
- 2. Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (2014) Contents of the SEER cancer statistics review (CSR), 1975–2011. [http://seer.](http://seer.cancer.gov/csr/1975_2011) [cancer.gov/csr/1975\\_2011](http://seer.cancer.gov/csr/1975_2011). Accessed 30 Jun 2014
- 3. Eulalio A, Huntzinger E, Izaurralde E (2008) Getting to the root of miRNA-mediated gene silencing. Cell 132:9–14
- 4. Grosshans H, Filipowicz W (2008) Molecular biology: the expanding world of small RNAs. Nature 451:414–416
- 5. Krebs JE, Goldstein ES, Kilpatrick ST (2009) Lewin's Genes X. Jones & Bartlett Learning, Sudbury
- 6. Lin P-Y, Yu S-L, Yang P-C (2010) MicroRNA in lung cancer. Br J Cancer 103:1144–1148
- 7. Li Y, Zhuang L, Wang Y, Hu Y, Wu Y, Wang D, Xu J (2013) Connect the dots: a systems level approach for analyzing the miRNA-mediated cell death network. Autophagy 9:436–439
- 8. Xu J, Liao X, Lu N, Liu W, Wong C-W (2011) Chromatinmodifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. Int J Cancer 129:2527–2531
- 9. Xu J, Wang Y, Tan X, Jing H (2012) MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. Autophagy 8:873–882
- 10. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu C-G, Croce CM, Harris CC (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198
- 11. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28:1721–1726
- 12. Yu S-L, Chen H-Y, Chang G-C, Chen C-Y, Chen H-W, Singh S, Cheng C-L, Yu C-J, Lee Y-C, Chen H-S, Su T-J, Chiang C-C, Li H-N, Hong Q-S, Su H-Y, Chen C-C, Chen W-J, Liu C-C, Chan W-K, Chen WJ, Li K-C, Chen JJW, Yang P-C (2008) MicroRNA

signature predicts survival and relapse in lung cancer. Cancer Cell 13:48–57

- 13. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous nonsmall-cell lung carcinoma. J Clin Oncol 27:2030–2037
- 14. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Edgar R (2007) NCBI GEO: mining tens of millions of expression profilesdatabase and tools update. Nucleic Acids Res 35:D760–D765
- 15. Ma L, Huang Y, Zhu W, Zhou S, Zhou J, Zeng F, Liu X, Zhang Y, Yu J (2011) An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PLoS One. doi:[10.](http://dx.doi.org/10.1371/journal.pone.0026502) [1371/journal.pone.0026502](http://dx.doi.org/10.1371/journal.pone.0026502)
- 16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249–264
- 17. Sales G, Coppe A, Bisognin A, Biasiolo M, Bortoluzzi S, Romualdi C (2010) MAGIA, a web-based tool for miRNA and genes integrated analysis. Nucleic Acids Res 38:W352–W359
- 18. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, Killcoyne S, Lotia S, Maere S, Morris J, Ono K, Pavlovic V, Pico AR, Vailaya A, Wang P-L, Adler A, Conklin BR, Hood L, Kuiper M, Sander C, Schmulevich I, Schwikowski B, Warner GJ, Ideker T, Bader GD (2007) Integration of biological networks and gene expression data using Cytoscape. Nat Protoc 2:2366–2382
- 19. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13:2498–2504
- 20. Huang DW, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44–57
- 21. Stelzer G, Inger A, Olender T, Iny-Stein T, Dalah I, Harel A, Safran M, Lancet D (2009) GeneDecks: paralog hunting and gene-set distillation with GeneCards annotation. OMICS 13:477–487
- 22. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D (2010) GeneCards version 3: the human gene integrator. Database (Oxford). doi:[10.](http://dx.doi.org/10.1093/database/baq020) [1093/database/baq020](http://dx.doi.org/10.1093/database/baq020)
- 23. Rappaport N, Nativ N, Stelzer G, Twik M, Guan-Golan Y, Stein TI, Bahir I, Belinky F, Morrey CP, Safran M, Lancet D (2013) MalaCards: an integrated compendium for diseases and their annotation. Database (Oxford). doi:[10.1093/database/bat018](http://dx.doi.org/10.1093/database/bat018)
- 24. Du L, Pertsemlidis A (2010) microRNAs and lung cancer: tumors and 22-mers. Cancer Metast Rev 29:109–122
- 25. Chen L, Lu M-H, Zhang D, Hao N-B, Fan Y-H, Wu Y-Y, Wang S-M, Xie R, Fang D-C, Zhang H, Hu C-J, Yang S-M (2014) miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. Cell Death Dis. doi:[10.1038/cddis.2013.553](http://dx.doi.org/10.1038/cddis.2013.553)
- 26. Zhu C-Q, Cutz J-C, Liu N, Lau D, Shepherd FA, Squire JA, Tsao M-S (2006) Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br J Cancer 94:1452–1459
- 27. Jia L, Wu J, Zhang L, Chen J, Zhong D, Xu S, Xie C, Cai J (2013) Restoration of miR-1228\* expression suppresses epithelial– mesenchymal transition in gastric cancer. PLoS One. doi:[10.](http://dx.doi.org/10.1371/journal.pone.0058637) [1371/journal.pone.0058637](http://dx.doi.org/10.1371/journal.pone.0058637)
- <span id="page-10-0"></span>28. Rani S, Gately K, Crown J, O'Byrne K, O'Driscoll L (2013) Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol Ther 14:1104–1112
- 29. Fu Q, Cash SE, Andersen JJ, Kennedy CR, Oldenburg DG, Zander VB, Foley GR, Simon Shelley C (2013) CD43 in the nucleus and cytoplasm of lung cancer is a potential therapeutic target. Int J Cancer 132:1761–1770
- 30. Seethala RR, Pasha TL, Raghunath PN, Livolsi VA, Zhang PJ (2008) The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol 16:165–172
- 31. Woo VL, Bhuiya T, Kelsch R (2006) Assessment of CD43 expression in adenoid cystic carcinomas, polymorphous lowgrade adenocarcinomas, and monomorphic adenomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:495–500
- 32. Kim H-J, Roh MS, Son CH, Kim AJ, Jee HJ, Song N, Kim M, Seo S-Y, Yoo YH, Yun J (2012) Loss of Med1/TRAP220 promotes the invasion and metastasis of human non-small-cell lung cancer cells by modulating the expression of metastasis-related genes. Cancer Lett 321:195–202
- 33. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, Zhai G, Zhao JH, Smith AV, Huffman JE, Albrecht E, Jackson CM, Evans DM, Cadby G, Fornage M, Manichaikul A, Lopez LM, Johnson T, Aldrich MC, Aspelund T, Barroso I, Campbell H, Cassano PA, Couper DJ, Eiriksdottir G, Franceschini N, Garcia M, Gieger C, Gislason GK, Grkovic I, Hammond CJ, Hancock DB, Harris TB, Ramasamy A, Heckbert SR, Heliovaara M, Homuth G, Hysi PG, James AL, Jankovic S, Joubert BR, Karrasch S, Klopp N, Koch B, Kritchevsky SB, Launer LJ, Liu Y, Loehr LR, Lohman K, Loos RJF, Lumley T, Al Balushi KA, Ang WQ, Barr RG, Beilby J, Blakey JD, Boban M, Boraska V, Brisman J, Britton JR, Brusselle GG, Cooper C, Curjuric I, Dahgam S, Deary IJ, Ebrahim S, Eijgelsheim M, Francks C, Gaysina D, Granell R, Gu X, Hankinson JL, Hardy R, Harris SE, Henderson J, Henry A, Hingorani AD, Hofman A, Holt PG, Hui J, Hunter ML, Imboden M, Jameson KA, Kerr SM, Kolcic I, Kronenberg F, Liu JZ, Marchini J, McKeever T, Morris AD, Olin A-C, Porteous DJ, Postma DS, Rich SS, Ring SM, Rivadeneira F, Rochat T, Sayer AA, Sayers I, Sly PD, Smith GD, Sood A, Starr JM, Uitterlinden AG, Vonk JM, Wannamethee SG, Whincup PH, Wijmenga C, Williams OD, Wong A, Mangino M, Marciante KD, McArdle WL, Meibohm B, Morrison AC, North KE, Omenaas E, Palmer LJ, Pietilainen KH, Pin I, Pola Sbreve Ek O, Pouta A, Psaty BM, Hartikainen A-L, Rantanen T, Ripatti S, Rotter JI, Rudan I, Rudnicka AR, Schulz H, Shin S-Y, Spector TD, Surakka I, Vitart V, Volzke H, Wareham NJ, Warrington NM, Wichmann H-E, Wild SH, Wilk JB, Wjst M, Wright AF, Zgaga L, Zemunik T, Pennell CE, Nyberg F, Kuh D, Holloway JW, Boezen HM, Lawlor DA, Morris RW, Probst-Hensch N,

Kaprio J, Wilson JF, Hayward C, Kahonen M, Heinrich J, Musk AW, Jarvis DL, Glaser S, Jarvelin M-R, Ch Stricker BH, Elliott P, O'Connor GT, Strachan DP, London SJ, Hall IP, Gudnason V, Tobin MD (2011) Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet 43:1082–1090

- 34. Chauchereau A, Mathieu M, de Saintignon J, Ferreira R, Pritchard LL, Mishal Z, Dejean A, Harel-Bellan A (2004) HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF. Oncogene 23:8777–8784
- 35. LLeonart ME, Vidal F, Gallardo D, Diaz-Fuertes M, Rojo F, Cuatrecasas M, Lopez-Vicente L, Kondoh H, Blanco C, Carnero A, Ramon y, Cajal S (2006) New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. Oncol Rep 16:603–608
- 36. UniProt Consortium (2014) Alpha-2, 8-sialyltransferase 8B-ST8SIA2-Homo sapiens (Human). In: UniProt. [http://www.uni](http://www.uniprot.org/uniprot/Q92186) [prot.org/uniprot/Q92186](http://www.uniprot.org/uniprot/Q92186). Accessed 15 Jul 2014
- 37. Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, Yanagihara K, Inui K, Oyanagi H, Yamada T, Nakayama J, Fujimoto I, Ikenaka K, Wada H (2001) Prognostic significance of polysialic acid expression in resected non-small cell lung cancer. Cancer Res 61:1666–1670
- 38. Tanaka F, Otake Y, Nakagawa T, Kawano Y, Miyahara R, Li M, Yanagihara K, Nakayama J, Fujimoto I, Ikenaka K, Wada H (2000) Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in nonsmall cell lung cancer. Cancer Res 60:3072–3080
- 39. Clark AS, West KA, Blumberg PM, Dennis PA (2003) Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 63:780–786
- 40. Fields AP, Regala RP (2007) Protein kinase Ci: human oncogene, prognostic marker and therapeutic target. Pharmacol Res 55:487–497
- 41. Gurpide A, Perez-Gracia JL, Lopez-Picazo JM, Moreno M, Zubieta JL, Martin-Algarra S, Garcia-Foncillas J (2005) Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. Clin Lung Cancer 7:138–140
- 42. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE (2010) Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 16:5873–5882